Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
Clinical trial NCT07019337 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07019337
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-30
- Primary completion
- 2028-07-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.